See more : va-Q-tec AG (VAQTF) Income Statement Analysis – Financial Results
Complete financial analysis of OncoSec Medical Incorporated (ONCS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OncoSec Medical Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- Adamera Minerals Corp. (DDNFF) Income Statement Analysis – Financial Results
- STLLR Gold Inc. (STLR.TO) Income Statement Analysis – Financial Results
- Gecina SA (GFC.PA) Income Statement Analysis – Financial Results
- Travel + Leisure Co. (0M1K.L) Income Statement Analysis – Financial Results
- Athena Consumer Acquisition Corp. (ACAQ) Income Statement Analysis – Financial Results
OncoSec Medical Incorporated (ONCS)
About OncoSec Medical Incorporated
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.82M | 34.10M | 25.10M | 18.45M | 17.42M | 11.95M | 14.74M | 13.13M | 5.80M | 3.16M | 2.37M | 648.31K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.19M | 14.28M | 18.31M | 11.97M | 18.69M | 9.50M | 12.14M | 8.11M | 6.15M | 3.91M | 3.16M | 1.05M | 27.16K | 33.71K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.19M | 14.28M | 18.31M | 11.97M | 18.69M | 9.50M | 12.14M | 8.11M | 6.15M | 3.91M | 3.16M | 1.05M | 27.16K | 33.71K | 7.19K |
| Other Expenses | 28.86K | -704.00 | 185.05K | 440.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.01M | 48.38M | 43.41M | 30.42M | 36.11M | 21.45M | 26.89M | 21.24M | 11.95M | 7.06M | 5.53M | 1.70M | 27.16K | 33.71K | 7.19K |
| Cost & Expenses | 37.01M | 48.38M | 43.41M | 30.42M | 36.11M | 21.45M | 26.89M | 21.24M | 11.95M | 7.06M | 5.53M | 1.70M | 27.16K | 33.71K | 7.19K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 20.93K | 15.86K | 5.11K | 3.81K | 6.37M | 0.00 | 0.00 | 0.00 | 20.68K | 83.22K | -3.16M | 1.36K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.10M | 1.08M | 1.18M | 683.75K | 3.67M | 379.99K | 355.58K | 664.60K | 780.11K | 736.88K | 717.45K | 250.82K | -9.00K | 0.00 | 0.00 |
| EBITDA | -35.92M | -47.30M | -42.23M | -29.73M | -32.43M | -21.07M | -26,886.05B | -21.24B | -11.95B | -7.06B | -4.81M | -1.70B | -36.16K | -33.71K | -7.19K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.01M | -48.38M | -43.41M | -30.42M | -36.11M | -21.45M | -26.89M | -21.24M | -11.95M | -7.06M | -5.53M | -1.70M | -27.16K | -33.71K | -7.19K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -501.72K | 800.14K | 283.07K | 141.92K | -3.03M | 0.00 | 0.00 | 0.00 | -20.68K | -83.22K | 3.16M | -2.06M | 9.00K | 0.00 | 0.00 |
| Income Before Tax | -37.51M | -47.58M | -43.13M | -30.27M | -39.14M | -21.45M | -26.89M | -21.24M | -11.97M | -7.15M | -2.36M | -3.76M | -18.16K | -33.71K | -7.19K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -3.33M | -2.41M | -872.59K | 1.30K | 680.00 | 1.39K | 2.46K | 1.97K | 41.77K | 2.00K | 2.40K | 1.60K | 9.00K | 0.00 | 0.00 |
| Net Income | -34.18M | -45.17M | -42.25M | -30.28M | -39.14M | -21.45M | -26.89M | -21.24M | -12.01M | -7.15M | -2.36M | -3.76M | -27.16K | -33.71K | -7.19K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -19.13 | -30.20 | -56.22 | -94.43 | -214.59 | -233.73 | -358.20 | -367.73 | -277.38 | -295.25 | -154.28 | -261.28 | -1.75 | -2.17 | -0.46 |
| EPS Diluted | -19.13 | -30.20 | -56.22 | -94.43 | -214.59 | -233.73 | -358.20 | -367.73 | -277.38 | -295.25 | -154.28 | -261.28 | -1.75 | -2.17 | -0.46 |
| Weighted Avg Shares Out | 1.79M | 1.50M | 751.57K | 320.60K | 182.38K | 91.77K | 75.07K | 57.77K | 43.31K | 24.22K | 15.33K | 14.39K | 15.56K | 15.56K | 15.56K |
| Weighted Avg Shares Out (Dil) | 1.79M | 1.50M | 751.57K | 320.60K | 182.38K | 91.77K | 75.07K | 57.77K | 43.31K | 24.22K | 15.33K | 14.39K | 15.56K | 15.56K | 15.56K |
E. League: Milan ai gironi vince 11-10 col Rio Ave - Lombardia
Solvay vince nuovamente una causa brevettuale in Germania
Utile annuale di Close Brothers Group: duro colpo per il COVID-19 | Invezz
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
Alliance Global Partners Lowers OncoSec Medical (NASDAQ:ONCS) Price Target to $6.50
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Vaccine Makers BioNTech, Moderna, And Novavax Set To Run Higher
Global Nivolumab Market 2020 Industry Analysis by Key Players, Product Type, Application, Regions and Forecast to 2026
Source: https://incomestatements.info
Category: Stock Reports